The existence or absence of generic adagrasibu and its price trends

Adagrasib (Adagrasib), as a small molecule inhibitor targeting the KRAS G12C mutant protein, has been successfully marketed in many overseas countries and is mainly used to treat adult non-small cell lung cancer (NSCLC). Recently, generic drugs of adagrasib have been released and entered the market. This innovation undoubtedly provides new treatment options for more patients.

Generic drugs are highly consistent with original drugs in terms of ingredients, but there may be certain differences in production specifications and prices. As the world's first similar product of its kind, the price of this generic drug of adagrasibu has dropped significantly compared to the original drug, and may even be only one-tenth of the original drug. This will undoubtedly bring benefits to patient families with greater financial pressure.

Since the original drug of adagrasibu has not yet been launched in China, domestic patients are currently unable to directly purchase this drug. The price of the American version of the original adagrasib drug sold overseas is as high as hundreds of thousands of yuan, which is undoubtedly a heavy financial burden for many families. In comparison, the newly launched generic drug of adagrasibu has more advantages in price. The price of a box of generic drug of 200mg*90 tablets is around RMB 4,000 (the price may fluctuate due to the exchange rate).

Although the price of generic adagrasibu is relatively affordable, patients still need to be cautious when using it. It is recommended that patients take drug treatment under the guidance of a doctor and ensure that they purchase drugs from regular channels to ensure the quality and safety of the drugs. At the same time, we also hope that the original drug or generic drugs of adagrasib can be introduced into the country as soon as possible to provide treatment options for more domestic patients.